Skip to contentpdufa.bio

nexiguran ziclumeran (nex-z)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

nexiguran ziclumeran (nex-z) is an Intellia Therapeutics, Inc. program in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

NTLA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Sponsor: Intellia Therapeutics, Inc. (NTLA). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Nov 18, 2026NTLA

Specialist biotech funds holding NTLA, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors829,053$10.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is nexiguran ziclumeran (nex-z)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for nexiguran ziclumeran (nex-z); no FDA decisions are on record below.

What happened at nexiguran ziclumeran (nex-z)'s most recent FDA decision?

No FDA decision for nexiguran ziclumeran (nex-z) is in our archive yet.

What is nexiguran ziclumeran (nex-z) used for?

In our records nexiguran ziclumeran (nex-z) is under review or in development for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

Who makes nexiguran ziclumeran (nex-z)?

Intellia Therapeutics, Inc. (NTLA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.